TY - JOUR T1 - Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19 JO - Reumatología Clínica (English Edition) T2 - AU - Muñoz-Jiménez,Alejandro AU - Rubio-Romero,Esteban AU - Fuente,José Luis Marenco de la SN - 21735743 M3 - 10.1016/j.reumae.2020.04.012 DO - 10.1016/j.reumae.2020.04.012 UR - https://reumatologiaclinica.org/en-proposal-for-use-anakinra-in-articulo-S2173574321000952 AB - The outcome of the SARS-CoV-2 (COVID-19) infection fundamentally affects the lung field, causing ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS). This process is an inflammatory picture, involving an NLRP3 INFLAMOSOME-triggered cytokine storm, the main player in alveolar destruction. IL-1 beta stands out among the cytokines that are triggered in this picture. ANAKINRA is a potent biological drug, capable of blocking this IL 1 beta. We propose its use in controlling ARDS secondary to COVID-19 infection. ER -